Editor’s introduction to the wide range of topics in the initial issue of the second volume of GaBI Journal
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 1
Abstract
We start off the second year of GaBI Journal with articles covering a wide range of issues.
Authors and Affiliations
Philip D Walson
Keywords
Related Articles
- EP ID EP355058
- DOI 10.5639/gabij.2013.0201.015
- Views 106
- Downloads 0
Statistical considerations for the development of biosimilar products
As the patents of a growing number of biological medicines have already expired or are due to expire, it has led to an increased interest from both the biopharmaceutical industry and the regulatory agencies in the develo...
Interchangeability. An insurmountable fifth hurdle?
The arrival of biosimilars has led to considerable debate on how they can be used in clinical practice. A particular concern is related to the question of whether a biosimilar can be safely interchanged with the originat...
Top developments in biosimilars during 2013
The past year has been a busy one for the biosimilars industry. Perhaps one of the most important milestones during 2013 was the European approval of the first monoclonal antibody biosimilar [Remsima/Inflectra (inflixima...
Understanding the components of pharmaceutical expenditure—overview of pharmaceutical policies influencing expenditure across European countries
Aim: To explain the components of pharmaceutical expenditure and illustrate the strengths and limitations of this indicator. In particular, we explore policies applied in European countries that affect the price and volu...
Biosimilars in oncology: current and future perspectives
Cancer represents a significant, and growing, burden on healthcare systems. This is driven, at least in part, by escalating cancer drug budgets. Loss of patent protection on biopharmaceuticals enables the development and...